Health-related quality of life for persons treated or monitored for anal high-grade squamous intraepithelial lesions (AMC-A01) Journal Article
| Authors: | Atkinson, T. M.; Mazumdar, M.; Van Hyfte, G.; Lee, J. Y.; Li, Y.; Lynch, K. A.; Webb, A.; Holland, S. M.; Lubetkin, E. I.; Goldstone, S.; Einstein, M. H.; Stier, E. A.; Wiley, D. J.; Mitsuyasu, R.; Rosa-Cunha, I.; Aboulafia, D. M.; Dhanireddy, S.; Schouten, J. T.; Levine, R.; Gardner, E. M.; Dunlevy, H.; Barroso, L. F.; Bucher, G.; Korman, J.; Stearn, B.; Wilkin, T. J.; Ellsworth, G.; Pugliese, J. C.; Cella, D.; Berry-Lawhorn, J. M.; Palefsky, J. M. |
| Article Title: | Health-related quality of life for persons treated or monitored for anal high-grade squamous intraepithelial lesions (AMC-A01) |
| Abstract: | PURPOSE The Anal Cancer/High-grade squamous intraepithelial lesions Outcomes Research (ANCHOR) trial demonstrated that treating precancerous anal HSIL reduces the incidence of anal cancer by 57% in people with HIV. It remains unclear how HSIL treatment or monitoring without treatment affects patient-reported health-related quality of life (HRQoL). We evaluated differences in HRQoL for individuals who were randomly assigned to active monitoring (AM) or treatment for anal HSIL. METHODS Using an index designed and validated for use in ANCHOR, HRQoL was assessed before random assignment (T1), 2-7 days (+3 days) after random assignment/treatment (T2), and 28 days (±7 days) after random assignment/treatment (T3). RESULTS ANCHOR participants living with HIV (N = 124; mean [standard deviation, SD] age, 52.6 years [10.3]; n = 101 [81.5%] men; n = 65 [52.4%] White; n = 95 [76.6%] non-Hispanic; treatment n = 70 [56.4%]; and AM n = 54 [43.6%]) were included. Treatment arm participants had significant mean worsening from T1-T2 in physical symptoms (mean [SD] difference, 0.31 [0.51]; P =.0001) and impact on psychological functioning (mean [SD] difference, 0.25 [0.64]; P =.022) that significantly improved to T1 levels from T2-T3 (ie, mean [SD] difference, -0.25 [0.52]; P =.003; and mean [SD] difference, -0.07 [0.23]; P =.039, respectively). AM arm participants experienced significant mean improvement in impact on psychological functioning from T1-T3 (mean [SD], difference, -0.20 [0.50]; P =.017). After adjusting for T1, treatment arm participants had a larger mean improvement than AM arm participants in physical symptoms from T2-T3 (mean [SD] difference, -0.25 [0.52]; P =.024); no between-arm differences were observed for impact on physical or psychological functioning. CONCLUSION Treatment arm participants experienced significant worsening in physical symptoms and impact on psychological functioning from T1-T2 but returned to prerandomization levels by T3, indicating that any immediate anal HSIL treatment-related impacts to HRQoL are temporary. Further research is needed to determine long-term impacts of anal HSIL treatment on HRQoL. © 2025 by American Society of Clinical Oncology. |
| Journal Title: | JCO Oncology Practice |
| ISSN: | 2688-1527 |
| Publisher: | American Society of Clinical Oncology |
| Publication status: | Online ahead of print |
| Date Published: | 2025-03-06 |
| Online Publication Date: | 2025-03-06 |
| Language: | English |
| DOI: | 10.1200/op-24-00830 |
| PUBMED: | 40048673 |
| PROVIDER: | scopus |
| PMCID: | PMC12221156 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Thomas Atkinson -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work